Ribometrix Incis A Preclinical Stage Biotechnology Company Based In Research Triangle Parknorth Carolinafounded In 2014The Company Specializes In Rna Targeted Small Molecule Therapeutics Aimed At Addressing Diseases By Modulating Rna Biologyribometrix Develops Small Molecules That Target Functional 3D Rna Structures To Inhibit The Production Of Disease Causing Proteins At The Translational Levelfocusing On Conditions With Traditionally Undruggable Protein Targets The Company Utilizes A Proprietary Platform That Integrates Rna Structure Determination Technology With Small Molecule Drug Discoverythis Approach Allows Ribometrix To Identify And Optimize Compounds That Can Modulate Rna Protein Interactions And Target Mrna Blueprints Of Disease Related Proteinsribometrix Collaborates With Strategic Partners To Advance Its Drug Development Efforts And Has Received Federal Funding To Support Its Initiativesthe Company Is Recognized As A Great Place To Workpromoting A Collaborative Environment Centered On Rna Biology Research
